Direct Contribution

Direct contributions are immediately available for Combs Lab Inc. (CLI) to complete the development of an oral drug for Type 1 Diabetes.  These funds will be transfered to a trust account maintained by the law firm for  CLI, Wyrick Robbins Yates & Ponton LLP (WRYP). CLI will only ask WRYP for funds from this account to complete milestones described in the project plan. Please click the DONATE button above if you want to support CLI's development of an oral drug for Type 1 Diabetes with a direct contribution.

Third Party Option

Contributions made through the Third Party Option also go towards  CLI's development of an oral drug for Type 1 Diabetes with the expectation that specific conditions are met before the funds are released. Third party option contributions are submitted to the law firm for CLI, Wyrick Robbins Yates & Ponton LLP (WRYP). WRYP will only transfer funds to CLI upon the donor’s request. If you want to support CLI's development of an oral drug for Type 1 Diabetes using the third party option, please contact Chris Lynch  at WRYP by phone  (919-781-4000) or email (  

                  Combs Lab Inc. 

Developing the first oral drug for Type 1 Diabetes
THE DEVELOPMENT OF A NonInsulin Oral Drug for Type 1 Diabetes

In the last 5-10 years, the major pharmaceutical companies reduced the size of their drug development operations in the US creating a unique opportunity for independent start-ups to fill the void. In 2010, Dr. Terry Combs and his team at the University of North Carolina (UNC) discovered a way to develop an oral drug for Type 1 Diabetes (T1D).  The technology is based on the fact that insulin is not the only thing missing in a person with T1D and insulin therapy DOES NOT restore the body to the nondiabetic state. UNC filed US, Canadian and European patent applications claiming the rights for this technology. In 2011, Dr. Combs cofounded a C-corporation called Combs Lab Inc. (CLI) to use this technology.

CLI’s founding members include Terry Combs, Rachel Combs, Steve Friedman. CLI's strategic advisor for drug development is Dr. Tom Bailey. CLI’s legal affairs are managed by the law firm of Wyrick, Robbins, Yates and Ponton.  CLI is seeking support to eliminate the burden of T1D. CLI plays a similar role as organizations aiming to develop oral insulin formulations, self-monitored insulin pumps, the artificial pancreas, pancreatic transplants and stem cell regeneration of the beta cell.

The great majority of people living with T1D have to inject insulin 4-6 times a day. Patient adherence to insulin therapy is so challenging that  people with T1D are more likely to become blind, loose a limb, require dialysis, kidney transplant or die of heart disease, than the rest of the population. In addition to alleviating the personal burden of T1D, the benefits of an oral drug for T1D include significant reductions in the cost of treating T1D and T1D related complications.

The insulin therapy market for the treatment of T1D in the US is estimated at $10 billion per year. According to CLI, the development of an oral drug for T1D through early stage clinical trials will require 4 years and $5.3 million to complete.  The leading drug candidate will be sold to a fully integrated pharmaceutical company at the completion of early stage clinical trials.   

The funds needed to identify a lead drug in year 1 can be reduced by partnerships that provide lab space with access to equipment, chemical libraries, research supplies and research personnel. Research funding for the drug discovery process can be made available in steps on the grounds that specific milestones are met which provide clear indications of progress and success towards clinical trials.